Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 9/20 | 0.66 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL875993 | 0.95 | PTGER4 (0.71) | PTGER4PTGER2KDM4EMAPTPTGS1 | |
| SCHEMBL30331185 | 0.89 | PTGER4 (0.62) | PTGER4PTGER2KDM4EMAPTPTGS1 | |
| SCHEMBL24861953 | 0.89 | PTGER4 (0.62) | PTGER4PTGER2KDM4EMAPTPTGS1 | |
| SCHEMBL15239116 | 0.86 | PTGER4 (0.69) | PTGER4PTGER2KDM4EMAPTLMNA | |
| SCHEMBL876516 | 0.85 | PTGER4 (0.69) | PTGER4PTGER2KDM4EMAPTPPARG | |
| SCHEMBL26416648 | 0.85 | KDM4E (0.58) | PTGER4PTGER2KDM4EMAPTPTGS1 | |
| SCHEMBL24861820 | 0.85 | PTGER4 (0.93) | PTGER4PTGER2 | |
| SCHEMBL26416663 | 0.85 | PTGER4 (0.93) | PTGER4PTGER2 | |
| SCHEMBL876593 | 0.84 | PTGER4 (0.60) | PTGER4PTGER2KDM4EMAPTPTGS1 | |
| SCHEMBL876698 | 0.83 | PTGER4 (0.70) | PTGER4PTGER2KDM4EMAPTPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | PTGER4, PTGER3, PTGER2 | PTGER4 1/4885PTGER2 3/4885KDM4E 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.